Corvus Pharmaceuticals
Yahoo Finance • last month
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL,... Full story
Yahoo Finance • 2 months ago
Corvus outlines January data readout for soquelitinib extension study as Phase II atopic dermatitis trial set for Q1 2026
Earnings Call Insights: Corvus Pharmaceuticals (CRVS) Q3 2025 MANAGEMENT VIEW * CEO Richard Miller emphasized continued progress in the development of soquelitinib for atopic dermatitis and T cell lymphomas, highlighting the completion... Full story
Yahoo Finance • 2 months ago
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients... Full story
Yahoo Finance • 2 months ago
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November... Full story
Yahoo Finance • 3 months ago
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimu... Full story
Yahoo Finance • 3 months ago
Barclays initiates coverage on U.S. small & mid-cap biotech stocks
Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story
Yahoo Finance • 3 months ago
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nor... Full story
Yahoo Finance • 5 months ago
Corvus plans Phase II trial for soquelitinib in atopic dermatitis, targeting 200 patients with 12-week treatment window
Earnings Call Insights: Corvus Pharmaceuticals (CRVS) Q2 2025 MANAGEMENT VIEW * CEO Richard A. Miller stated the company's main focus remains the development of soquelitinib for atopic dermatitis, highlighting "an oral medication featu... Full story
Yahoo Finance • 5 months ago
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7,... Full story
Yahoo Finance • 6 months ago
Corvus Q1 2025 presentation: Phase 1 atopic dermatitis data drives stock surge
Introduction & Market Context Corvus Pharmaceuticals (NASDAQ:CRVS) presented its first quarter 2025 business update on May 8, highlighting promising clinical data for its lead drug candidate soquelitinib in atopic dermatitis. The presenta... Full story
Yahoo Finance • 6 months ago
Tuesday's Insider Activity: Major Buys and Sells Shake Up Markets
This article summarizes the top insider buys and sells reported on Tuesday, July 1, 2025, for US stocks. Top Insider Buys: Kymera Therapeutics Inc (NASDAQ:KYMR): A group of directors, including Mark N Lampert, collectively purchased $13... Full story
Yahoo Finance • 6 months ago
OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million
OrbiMed Advisors LLC, a major shareholder in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), sold 1,176,332 shares of common stock on June 27, 2025, for approximately $4.89 million. The shares were sold at a price of $4.1586. According to Inve... Full story
Yahoo Finance • 7 months ago
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings w... Full story
Yahoo Finance • 9 months ago
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webc... Full story
Yahoo Finance • 9 months ago
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has b... Full story
Yahoo Finance • 10 months ago
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration... Full story
Yahoo Finance • 10 months ago
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of... Full story
Yahoo Finance • 10 months ago
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings... Full story
Yahoo Finance • 10 months ago
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25... Full story
Yahoo Finance • 10 months ago
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclin... Full story
